Amrutanjan Health Care Ltd
₹ 522
-2.66%
24 Aug
- close price
About
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. [1]
Key Points
- Market Cap ₹ 1,509 Cr.
- Current Price ₹ 522
- High / Low ₹ 791 / 483
- Stock P/E 24.2
- Book Value ₹ 128
- Dividend Yield 0.94 %
- ROCE 24.8 %
- ROE 18.5 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 26.7%
- Company's working capital requirements have reduced from 123 days to 96.0 days
Cons
- The company has delivered a poor sales growth of 8.59% over past five years.
- Promoter holding has decreased over last 3 years: -3.51%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 154 | 174 | 207 | 220 | 253 | 261 | 333 | 406 | 380 | 421 | 452 | 503 | 511 | |
| 130 | 143 | 178 | 192 | 222 | 231 | 258 | 326 | 335 | 369 | 394 | 427 | 438 | |
| Operating Profit | 25 | 32 | 29 | 28 | 31 | 31 | 75 | 80 | 45 | 52 | 58 | 76 | 73 |
| OPM % | 16% | 18% | 14% | 13% | 12% | 12% | 22% | 20% | 12% | 12% | 13% | 15% | 14% |
| 5 | 6 | 7 | 8 | 7 | 8 | 11 | 15 | 15 | 16 | 18 | 9 | 6 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 | 6 | 7 |
| Profit before tax | 26 | 35 | 34 | 33 | 35 | 34 | 82 | 91 | 54 | 62 | 69 | 78 | 73 |
| Tax % | 35% | 35% | 35% | 39% | 29% | 27% | 25% | 26% | 26% | 27% | 26% | 26% | |
| 17 | 22 | 22 | 20 | 25 | 25 | 61 | 67 | 40 | 45 | 51 | 58 | 54 | |
| EPS in Rs | 5.86 | 7.68 | 7.47 | 6.84 | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 | 15.55 | 17.58 | 20.03 | 18.67 |
| Dividend Payout % | 30% | 25% | 26% | 22% | 26% | 24% | 20% | 20% | 34% | 30% | 26% | 24% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 9% |
| 3 Years: | 10% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 1% |
| 3 Years: | 17% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -6% |
| 3 Years: | -5% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 18% |
| 3 Years: | 17% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 102 | 118 | 113 | 126 | 143 | 156 | 213 | 262 | 288 | 286 | 324 | 367 |
| 0 | 0 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | |
| 25 | 28 | 34 | 38 | 42 | 44 | 57 | 84 | 70 | 77 | 93 | 137 | |
| Total Liabilities | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 509 |
| 13 | 22 | 27 | 28 | 26 | 26 | 23 | 28 | 49 | 50 | 49 | 51 | |
| CWIP | 4 | 1 | 1 | 0 | 0 | 0 | 2 | 17 | 1 | 2 | 16 | 105 |
| Investments | 14 | 10 | 10 | 8 | 18 | 18 | 18 | 13 | 5 | 0 | 0 | 3 |
| 100 | 116 | 115 | 131 | 144 | 161 | 232 | 291 | 307 | 315 | 356 | 349 | |
| Total Assets | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 509 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19 | 21 | 8 | 19 | 21 | 18 | 91 | 52 | 20 | 28 | 51 | 36 | |
| -5 | 1 | -0 | -8 | -11 | -14 | -88 | -36 | -2 | 19 | -31 | -21 | |
| -12 | -11 | -5 | -9 | -7 | -12 | -7 | -17 | -15 | -48 | -13 | -14 | |
| Net Cash Flow | 2 | 12 | 3 | 2 | 3 | -7 | -4 | -1 | 3 | -1 | 6 | 1 |
| Free Cash Flow | 13 | 20 | 5 | 18 | 19 | 16 | 89 | 29 | 11 | 21 | 15 | -19 |
| CFO/OP | 114% | 104% | 77% | 105% | 101% | 95% | 146% | 96% | 81% | 86% | 118% | 73% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62 | 55 | 51 | 46 | 47 | 37 | 19 | 34 | 32 | 42 | 45 | 44 |
| Inventory Days | 44 | 44 | 44 | 40 | 45 | 74 | 45 | 53 | 58 | 50 | 45 | 56 |
| Days Payable | 46 | 51 | 110 | 102 | 92 | 98 | 106 | 122 | 95 | 96 | 113 | 106 |
| Cash Conversion Cycle | 61 | 48 | -15 | -16 | 0 | 13 | -41 | -35 | -6 | -5 | -23 | -6 |
| Working Capital Days | 42 | 45 | 76 | 26 | 30 | 70 | 28 | 92 | 117 | 173 | 99 | 96 |
| ROCE % | 26% | 29% | 28% | 25% | 25% | 23% | 44% | 38% | 19% | 21% | 22% | 25% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Comfy (Women's Hygiene) Net Sales INR Crore |
|
|||||||||
| Pain Management (Brand Amrutanjan) Net Sales INR Crore |
||||||||||
| Electro+ (Rehydration) Net Sales INR Crore |
||||||||||
| Number of Employees count |
||||||||||
| Total Distribution Outlets Lakhs |
||||||||||
| OTC Production Volume Tonnes |
||||||||||
| Number of Distributors count |
||||||||||
| Number of Countries (International Presence) count |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Investor Presentation For The Quarter Ended 30Th June 2026
-
Record Date For The Final Dividend And AGM
- 11 September 2026 record date fixed for FY26 final dividend.
-
Board Meeting Outcome for Financial Results And Outcome Of The Board Meeting
- Q1 FY27 results approved; PAT Rs 436.57 lakh. AGM on 23 Sep 2026; record date 11 Sep.
-
Additional Details Required For Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations, 2015,
- Amrutanjan explains delay in Regulation 30 credit rating intimation; seeks condonation.
-
Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results For The Quarter Ended 30Th June 2026
- Board to meet on 11 August 2026 to approve Q1 FY27 unaudited results; trading window closed till 13 August.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Concalls
-
Aug 2026TranscriptAI SummaryPPT
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Sep 2024TranscriptPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Aug 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
May 2019TranscriptAI SummaryPPT
Business Overview:[1]
Amrutanjan Health Care operates across OTC healthcare, women’s hygiene, beverages and personal care. Its key brands include Amrutanjan in pain management, Relief in congestion, Comfy in women’s hygiene, Electro+ and Enerlyte in rehydration, and Fruitnik in fruit-based beverages. Company entered personal care in Q4 FY26 through men’s and women’s razors. It also operates an Advanced Pain Management Centre in Chennai.